The impact of baseline coronary plaque burden on the clinical outcome in patients receiving aggressive low-density lipoprotein cholesterol (LDL-C) lowering therapy to levels ,70 mg/dL is unknown. We assessed the prognostic significance of baseline coronary plaque burden following high-intensity statin therapy.
Introduction
Atherosclerosis, a systemic disease, 1 forms the substrate for the majority of ischemic cardiovascular events. Considerable evidence from autopsy and vascular imaging studies relates the burden of atherosclerosis to its clinical sequelae. 2 -8 Intravascular ultrasound (IVUS) has evolved as an imaging modality that generates high-resolution, precise volumetric quantification of epicardial coronary atherosclerosis. By measuring the change in atheroma volume over time, IVUS can evaluate the potential anti-atherosclerotic efficacy of interventions on plaque development. 9 There is a well-established relationship between low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events, and substantial evidence from numerous randomized, clinical trials corroborates the clinical benefit of statin-mediated LDL-C lowering. 10 Clinical guidelines emphasize lowering LDL-C to levels ,100 mg/dL in patients with documented coronary artery disease, 11 with further lowering to ,70 mg/dL in higher-risk individuals. 12, 13 High-dose statin therapy halts the progression, 14 and regresses coronary atherosclerosis, 15, 16 and lowers clinical event rates. 17, 18 This clinical benefit is most pronounced in patients at greatest risk for future cardiovascular events. 10, 19 However, statin-treated patients continue to experience clinical events, indicative of a substantial degree of residual risk. While the baseline coronary atheroma volume on IVUS associates with adverse cardiovascular events, 6 no study has evaluated the prognostic significance of atheroma burden in patients treated with intensive statin therapy, with achieved LDL-C levels ,70 mg/dL. The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin vs. Atorvastatin (SATURN; ClinicalTrials.gov number, NCT000620542) assessed progression of coronary atherosclerosis in patients treated with the highest doses of atorvastatin and rosuvastatin. 16 The current analysis determined the relationship between IVUS-derived baseline coronary atheroma volume and subsequent major adverse cardiovascular events (MACE) in patients achieving very low LDL-C levels with high-intensity statin therapy.
Methods

Patient selection
The design of SATURN has been previously described. 16, 20 Briefly, patients with angiographically demonstrable coronary disease and LDL-C ,116 mg/dL following a 2-week treatment period with atorvastatin 40 mg or rosuvastatin 20 mg daily were re-randomized and treated for 24 months with atorvastatin 80 mg or rosuvastatin 40 mg daily. Subjects underwent IVUS imaging of a coronary artery at baseline and after 104 weeks of treatment.
Acquisition and analysis of intravascular coronary imaging
The presence of at least a single lumen stenosis of .20% angiographic diameter stenosis severity in an epicardial coronary artery at the time of a clinically indicated coronary angiogram was necessary for enrollment. IVUS was performed at baseline in a single, native coronary artery with no lumen stenosis of .50%, which had not undergone revascularization and was not considered to be the culprit vessel of a prior myocardial infarction. Images were screened by the core laboratory at the Cleveland Clinic Coordinating Center for Clinical Research for imaging quality, and those patients whose baseline imaging was acceptable were eligible for randomization. Following 104 weeks of treatment, patients underwent repeat IVUS of the same artery. Anatomically matched arterial segments were selected for analysis on the basis of proximal and distal side branches (fiduciary points). Cross-sectional images spaced 1 mm apart were selected for analysis, with lumen and external elastic membrane (EEM) leading edges defined by manual planimetry. The plaque area was determined as the area between these leading edges. The percent atheroma volume (PAV) was calculated as the proportion of total vessel wall volume occupied by atherosclerotic plaque, as previously described. 6 The primary endpoint of SATURN, change in PAV, was calculated as the PAV at 104 weeks minus the corresponding PAV at baseline. Plaque regression was defined as any decrease in PAV from baseline.
Statistical analysis
The current post hoc analysis pooled both the treatment groups, given that they did not significantly differ in either baseline or change in PAV during the 2-year follow-up. Continuous variables were reported as mean + SD if normally distributed and as median (interquartile range) if non-normally distributed. Demographics, baseline clinical characteristics, follow-up medications, laboratory biochemical data, and baseline IVUS parameters were compared in patients with baseline PAV levels below and above the median PAV of 36.2%. Two-sample t tests were used for normally distributed continuous variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, and chi-square tests for categorical variables. Serial changes in IVUS measurements were analysed by analysis of variance adjusting for their baseline counterparts and were reported as least-squares mean + SE.
A multivariable logistic regression model was constructed for defining important predictors of baseline PAV below vs. above the median. Demographic data and clinical characteristics were entered into the model for variable selection with bootstrap re-sampling (1000 iterations and a P-value criterion of 0.1 for retention). Those variables having at least a 40% probability of retention were entered into a second logistic model with the stepwise model selection procedure. The significance level to enter and keep a variable was set at 0.05. The selected covariates formed the covariate set for the final multivariable logistic model.
To evaluate the potential relationship of baseline PAV with MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina), log-rank tests with Kaplan-Meier figures in addition to unadjusted and adjusted Cox proportional hazards regression models were created. The adjusted Cox models were created using the same variable selection procedures as the multivariable logistic model, with baseline PAV forced into the model. For the Cox models, the risk factors met the proportional hazards assumption by plotting the log of the negative log of their estimated survival distribution, log (2log(S(t))), vs. time, and the linearity assumption was assessed and satisfied for all continuous variables by plotting the log hazard ratio against the continuous variable as well as testing the linear hypotheses. To understand better the relationships between MACE, plaque burden, and lipids, similar Cox models were created for baseline LDL-C and for on-treatment (time-weighted average) LDL-C.
These survival analyses applied a cut-off date of 24 months, and used the time to first occurrence of MACE for analysis. Patients with no MACE by 24 months were censored at this time point. The MACE analysis was conducted on patients who were randomized according to the treatment regimen (n ¼ 1385) and, therefore, included some patients who did not undergo IVUS imaging at follow-up. All other analyses were based on the modified intent-to-treat population, which included all patients with a baseline and follow-up IVUS measurement (n ¼ 1039). For this study, no adjustments for multiple comparisons were made. A two-sided P-value of ,0.05 was considered statistically significant. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA). Table 2 describes lipid and C-reactive protein (CRP) levels at baseline and follow-up, and changes from baseline. Patients with a baseline PAV above the median had levels of LDL-C which were similar to those whose PAV was below the median at baseline (119.0 + 29 vs. 121.0 + 27 mg/dL, P ¼ 0.09), and at follow-up (65.3 + 23 vs. 65.8 + 22 mg/dL, P ¼ 0.47). Patients with a lower baseline PAV had higher baseline high-density lipoprotein cholesterol (HDL-C) (46.3 + 11.6 vs. 43.7 + 10.8 mg/dL, P , 0.001), higher baseline apolipoprotein A-1 ApoA-1 (129.6 + 24.9 vs. 124.7 + 23.4 mg/dL, P ¼ 0.005) levels, but a lower baseline ratio of apolipoprotein B (ApoB):ApoA-1 (0.84 + 0.22 vs. 0.87 + 0.26, P ¼ 0.04) and lower baseline levels of CRP [1.5 mg/L (0.7, 3.3) vs. 1.8 (0.9, 3.6), P ¼ 0.03], compared with those with a baseline PAV greater than the median. Patients with a baseline PAV above the median demonstrated a greater increase in levels of HDL-C (13.0 + 18.9 vs. 9.7 + 17.6%, P ¼ 0.002) and ApoA-1 (14.6 + 18.9 vs. 12.2 + 16.6%, P ¼ 0.055) during follow-up. In patients whose baseline PAV was greater than the median, the follow-up ApoB/A-I ratio was higher than those with a baseline PAV less than the median (0.54 + 0.16 vs. 0.53 + 0.16, P ¼ 0.03).
Results
Patient characteristics
Laboratory measurements
Baseline and changes in coronary intravascular ultrasound measurements , P ¼ 0.62) were similar in the two groups.
Factors associated with coronary atheroma volume at baseline Table 4 presents the factors that were associated with a greater compared with lesser baseline PAV on multivariable logistic regression analysis. Male sex (P ¼ 0.001), hypertension (P ¼ 0.004), diabetes mellitus (P ¼ 0.03), and increasing age (P ¼ 0.02) all associated with a higher baseline PAV. Baseline use of antiplatelet medication (P ¼ 0.006), higher baseline body-mass index (BMI, P ¼ 0.03), and higher baseline HDL-C (P ¼ 0.003) were more likely to be associated with a lower baseline PAV.
Relationship between coronary atheroma volume, low-density lipoprotein cholesterol-C levels and cardiovascular events
In SATURN, 101 patients experienced a total of 143 MACE (death 4, non-fatal myocardial infarction 22, stroke 5, hospitalizations for unstable angina 29, coronary revascularization procedures 83). Figure 1 shows the association between baseline PAV, baseline LDL-C, and on-treatment LDL-C with time-to-first MACE. (Figure 2) . Patients with the highest quartile of baseline PAV (.41.8%) had a 2-year cumulative incidence of MACE of 12% (log-rank test P ¼ 0.001 compared with all lower PAV quartiles combined). MACE rates for quartiles 3, 2, and 1 for baseline PAV were 5.7, 7.9, and 5.1% respectively.
Discussion
SATURN was the largest imaging study to compare the antiatherosclerotic efficacy of two potent statins, each prescribed at maximal approved doses. 16 As the majority of patients enrolled in SATURN were followed clinically and serially with IVUS over 2 years, there was sufficient statistical power to explore the prognostic significance of baseline coronary atheroma volume in the setting of very low on-treatment LDL-C levels. This study has three chief findings. First, despite on-treatment LDL-C levels falling ,70 mg/dL following high-intensity statin therapy, baseline coronary atheroma volume remained strongly associated with subsequent MACE, with increasing quartiles of atheroma volume being associated significantly with corresponding increments of cumulative MACE. These associations remained significant despite accounting for levels of LDL-C. Second, patients with a higher (greater than the median) baseline coronary atheroma volume experienced more pronounced disease regression and lumen expansion following potent statin therapy, compared with patients with lesser (below the median) atheroma volume at baseline. Third, in the SATURN population, male sex and common coronary risk factors were more likely to associate with greater coronary atheroma volume being present at baseline.
A prior pooled analysis of more than 4000 patients who underwent serial coronary IVUS in six clinical trials demonstrated that the baseline extent of coronary atheroma volume was independently associated with subsequent incident clinical events, 6 although a pooled analysis such as this may have been subject to potential confounding by inclusion of studies with differing treatments and entry criteria. Accordingly, single large-scale trials provide a more robust level of evidence. Furthermore, this pooled analysis was conducted in the setting of on-treatment LDL-C levels of 90 mg/dL, well above the levels currently recommended by clinical guidelines. In patients with established coronary artery disease, guidelines now advocate LDL-C lowering to levels ,70 mg/dL, particularly in higher-risk patients. 13 The current analysis indicates that the baseline coronary atheroma volume remains a significant prognostic factor even when the achieved level of LDL-C is ,70 mg/dL, induced by the highest approved doses of the most potent statins currently on the market. Current clinical practice involves measuring cholesterol levels to assess cardiovascular risk. 21 Considerable clinical evidence supports that aggressive lowering of LDL-C improves clinical outcomes over less intense therapy. 10 Despite a mean on-treatment LDL-C level Coronary atheroma volume and clinical events on IVUS of 66 mg/dL in SATURN, this study reports the novel finding that the baseline coronary atheroma volume continues to associate significantly with MACE. Each standard deviation increase in IVUS-derived baseline PAV was associated with a nearly 1.3-fold higher risk of MACE. The cumulative MACE in patients in the highest quartile of baseline PAV was more than double than those in the lowest quartile (12 vs. 5.1%, P ¼ 0.003). The finding however, of a lack of an association between LDL-C levels and MACE in SATURN deserves specific comment. The reasons for these findings warrant further investigation. While at first glance this finding may seem at odds with prevailing views of the prognostic importance of LDL-C levels, it should not diminish the substantial body of evidence of LDL-C per se as an important, validated biomarker for predicting clinical events in large-scale population studies. 21 Rather, SATURN was unique, in that all patients received the highest approved doses of the most potent statins available on the market, which is in contrast to the doses of statins used by many outcome studies. 22 The present finding demonstrates the powerful short-to-medium term prognostic capacity of disease burden, above and beyond the capacity of cardiovascular risk factors and significant LDL-C lowering. Plaque burden per se reflects a lifetime exposure to all cardiovascular risk factors, is systemically expressed, forms the direct substrate for cardiovascular events and may thus simply represent a more powerful short-to-medium term marker of cardiovascular risk. Patients with a greater baseline burden of disease were also more likely to experience coronary atheroma regression during the treatment period. Such patients were more likely to be male, older age, diabetic, and hypertensive. This suggests that these higher-risk patients may also harbour a more modifiable atherosclerotic lesion substrate. These findings highlight the significant degree of residual clinical risk imparted by the baseline extent of coronary disease, during a relatively short follow-up period of 2 years. Despite the substantial LDL-C lowering achieved by aggressive statin therapy in SATURN, this risk persisted. This finding has implications for the clinical utility of non-invasive imaging evaluation of plaque burden as a measure of cardiovascular risk in future clinical practice. Presently, there are no data to support non-invasive measures of atheroma burden as a means to improve prediction of clinical risk. Ultimately, supportive data from a large-scale trial will be critical to justify the alteration of treatment guidelines in favour of incorporating non-invasive imaging for this clinical application.
Atherosclerosis is a chronic, progressive disease, and its manifestations begin early in life. A recent study that used Mendelian randomization, followed by a large-scale meta-analysis, demonstrated that prolonged exposure to lower LDL-C levels earlier in life may substantially reduce the relative risk of incident cardiovascular events. 23 This raises the provocative question of whether active measures to lower LDL-C should begin earlier in life, in order to lower the cumulative burden of disease. The residual MACE rate observed in trials testing high-dose statin therapy provides some support to this notion. Our results also do not exclude the possibility of further clinical benefit from additional LDL-C lowering. Regression analyses of MACE or plaque regression vs. on-treatment LDL-C levels reveal a direct relationship, 16 without yet of any definitive evidence of a ceiling effect of benefit from further LDL-C lowering. The recent demonstration of the safety and efficacy of monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), 24, 25 as a strategy to incrementally lower LDL-C levels to below those already achieved by high-dose statins, offers the potential to even further regress coronary atheroma, and possibly lower clinical events. This will be tested in ongoing clinical trials. These findings also reflect the need for developing strategies beyond aggressive LDL-C lowering, whereby alternative therapeutic targets may yield a greater impact on the burden of disease, and its clinical consequences, when achieved LDL-C levels are very low. Increasing the levels of and promoting the function of HDL particles may represent an important therapeutic strategy in this setting. In SATURN, patients with higher baseline HDL-C levels were more likely to present with a lower baseline plaque burden, and atheroma regression is known to more commonly occur in the setting of both significant LDL-C lowering and rising HDL-C levels. 26 Inflammation appears to be implicit in the pathogenesis of atherosclerosis, 27 and strategies to reduce systemic inflammation may prove optimal in the setting of very low LDL-C. Similarly, lowering of triglycerides, particularly in patients with mixed dyslipidaemia, may also offer incremental benefit beyond aggressive LDL-C lowering in these high-risk individuals.
Several caveats of the current analysis should be noted. SATURN was not a placebo-controlled trial. All patients received potent statin therapy; hence, we could not assess whether the prognostic significance of baseline coronary atheroma volume in SATURN would have differed in the absence of such treatment. Statins, however, remain the backbone of our current armamentarium of antiatherosclerotic therapies. Therefore, it would be unethical to conduct such a study without using background statin therapy, particularly at doses that do not achieve LDL-C levels ,100 mg/dL, and possibly 70 mg/dL in patients with documented coronary disease. Patients enrolled in SATURN required demonstrable coronary artery disease. Therefore, our study findings cannot be extrapolated to individuals with asymptomatic, subclinical atherosclerosis. Indeed, the invasive nature of IVUS as a means to volumetrically quantify coronary atherosclerosis renders it unlikely to ever be utilized in such a low-risk population. It remains unknown whether the clinical events in SATURN were related to atherosclerosis demonstrated on IVUS, or from another diseased artery. This limitation is common to trials employing vascular imaging of a single artery and clinical followup. A prospective evaluation of patients who underwent three-vessel IVUS following acute coronary syndrome found that half of all incident clinical events stemmed from remote non-culprit lesions, 28 underscoring the systemic nature of the atherosclerotic disease process, and patient vulnerability. 29, 30 Similar to recently reported studies that evaluated the natural history of coronary atherosclerosis, 28, 31 MACE was driven largely by coronary revascularization, which could be subject to bias due to differing regional clinical strategies. However, events leading to revascularization are not benign, and despite the inherent risk attributable to coronary revascularization per se, 32 revascularization improves the morbidity and mortality of these patients. 32 -34 Furthermore, a post hoc analysis of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial found that achieved risk reductions of hard clinical events were similar to the combined endpoint that included coronary revascularization. 35 Finally, the association between the higher BMI and a lower baseline PAV is unclear, and deserves comment. A previous analysis found no relationship between obesity and baseline coronary plaque burden. 36 However, obesity (defined by BMI ≥30 kg/m 2 ) independently associated with PAV progression, 37 although patients with the highest BMI also derived the greatest benefit from potent statin therapy, demonstrating the greatest plaque regression. 36 These findings underscore the complex relationship between adiposity, cardiovascular risk, and response to anti-atherosclerotic therapies, comprising a major ongoing area of interest. In summary, following 2 years of maximally intensive statin therapy and the achievement of very-low on-treatment LDL-C levels, baseline coronary atheroma volume remained significantly associated with MACE. Patients with the highest baseline quartile of coronary atheroma volume demonstrated a greater than twofold higher cumulative MACE rate compared with those with the lowest quartile. These findings reinforce atherosclerotic disease burden as an important biomarker of clinical risk, and demonstrate the need for developing novel therapeutic anti-atherosclerotic strategies beyond those of aggressive LDL-C lowering, in order to further lower the complications arising from the residual burden of coronary disease.
